Dulaglutide Research & Listing Availability

Current Dulaglutide vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

Current Dulaglutide vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

About Dulaglutide

FDA-approvedAlso known as: Trulicity · LY2189265

Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved as Trulicity for type 2 diabetes in 2014. It is structurally distinct from peptide-class GLP-1 analogs: two GLP-1 analog peptide chains are covalently linked to a human IgG4-Fc fragment, producing a much larger ~63 kDa molecule with a ~5-day half-life.[1][2]

Each of the two GLP-1 arms binds the GLP-1 receptor independently. The IgG4-Fc scaffold confers an extended half-life through FcRn recycling rather than albumin binding (the mechanism semaglutide and liraglutide use). The size of the fusion protein keeps it largely in the vascular compartment and limits CNS penetration, which has been hypothesized to contribute to its comparatively milder nausea profile.

The AWARD program established A1C reductions of ~1.4–1.6% at 1.5mg weekly across nine Phase 3 trials.[3] REWIND (Gerstein et al., Lancet 2019) reported a 12% reduction in major adverse cardiovascular events in adults with T2D and a broad cardiovascular-risk profile — notably including a primary-prevention cohort, not just secondary-prevention.[4] AWARD-11 demonstrated dose-response gains at 3.0mg and 4.5mg.[5] Dulaglutide is the active comparator in the ongoing SURPASS-CVOT tirzepatide outcomes trial.[6]

Regulatory: FDA-approved as Trulicity (type 2 diabetes, 2014) with cardiovascular risk-reduction indication added 2020. Not approved for weight management as a standalone indication. Research-grade material sold for in vitro / non-clinical use only.

Read the full mechanism & research breakdown

Dulaglutide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Dulaglutide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Dulaglutide is unusual in the GLP-1 class. Most GLP-1 agonists are modified peptides (semaglutide, liraglutide, tirzepatide); dulaglutide is a fusion protein in which two copies of a GLP-1 analog peptide are covalently linked through a small peptide linker to the Fc region of a modified human IgG4 antibody.[2] The Fc scaffold confers an extended half-life of approximately 5 days through neonatal Fc receptor (FcRn) recycling — the same mechanism that gives IgG antibodies their long circulating life — rather than through albumin binding via a fatty-acid sidechain. The two GLP-1 arms bind the GLP-1 receptor independently and produce the standard incretin effects: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic appetite signalling. The large molecular weight (~63 kDa, versus ~5 kDa for semaglutide) limits passive CNS penetration and confines distribution largely to the vascular and interstitial compartments — the leading hypothesis for why dulaglutide trial protocols often report somewhat milder gastrointestinal symptoms at therapeutic doses than peptide-class GLP-1s do.

Active research areas

  • Type 2 diabetes (AWARD program)
    The AWARD program of nine Phase 3 trials established A1C reductions of approximately 1.4–1.6% at 1.5mg weekly across monotherapy, dual therapy with metformin, triple therapy, insulin combination, and head-to-head comparisons against insulin glargine, exenatide, and sitagliptin.[3]
  • Cardiovascular outcomes (REWIND)
    REWIND reported a 12% reduction in the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke over a median 5.4 years in adults with T2D. The trial is notable for enrolling a population of which only about 31% had established cardiovascular disease — the cardiovascular benefit held in the primary-prevention subgroup, extending the GLP-1 class signal beyond secondary prevention.[4]
  • High-dose dulaglutide (AWARD-11)
    AWARD-11 reported dose-dependent additional A1C and weight reductions at 3.0mg and 4.5mg weekly versus the standard 1.5mg dose, supporting the FDA label expansion to higher doses in 2020. The higher-dose data partially close the efficacy gap with semaglutide and tirzepatide for weight loss, though they do not match either drug.[5]
  • Renal outcomes (REWIND exploratory)
    A pre-specified renal-outcomes analysis of REWIND reported a 15% reduction in the composite of new macroalbuminuria, sustained ≥30% eGFR decline, or chronic renal replacement therapy — driven primarily by the macroalbuminuria component, in line with class-level findings.[7]
  • Cognitive function (REWIND exploratory)
    An exploratory cognitive analysis of REWIND reported a 14% reduction in incident substantive cognitive impairment over 5.4 years in adults with T2D, generating one of the strongest GLP-1-class signals in dementia research and motivating subsequent dedicated trials of the class in early Alzheimer's disease.[8]
  • Active-comparator role in SURPASS-CVOT
    Dulaglutide 1.5mg is the active comparator in the ongoing SURPASS-CVOT outcomes trial of tirzepatide — the first major head-to-head GLP-1 vs. GIP/GLP-1 cardiovascular comparison, with primary readout expected in 2026.[6]
Open questions & leading hypotheses (2)
  • Hypothesis: Dulaglutide's Fc-fusion design will be displaced by peptide-class GLP-1s for weight-loss indications but retain a role in T2D where the cardiovascular and renal evidence base is strongest.
    Evidence: Even at the AWARD-11 high doses, weight loss with dulaglutide trails semaglutide and substantially trails tirzepatide;[5] the molecule has never been pursued for an obesity indication. Counter-evidence: dulaglutide has the broadest cardiovascular outcomes dataset including primary prevention (REWIND), the most accessible once-weekly auto-injector device, and the cognitive-function signal from REWIND that is unmatched in the class — clinical use in T2D has been resilient despite the newer competitors.
  • Hypothesis: The cognitive benefit signal in REWIND reflects a true neuroprotective effect of GLP-1 receptor signalling that warrants dedicated dementia trials.
    Evidence: GLP-1 receptors are expressed in hippocampus and cortex, animal models show neuroprotection in Alzheimer-relevant assays, and the REWIND signal was pre-specified and showed effect-size consistency across subgroups.[8] Counter-evidence: REWIND was a cardiovascular trial with cognitive function as an exploratory secondary outcome — the cognitive instrument was brief, drop-out rates were significant, and the signal could reflect general health benefits of better-controlled diabetes rather than a direct neuroprotective effect. Dedicated Phase 3 dementia trials of the class (EVOKE for semaglutide) will be the definitive test.
What community users report

Anecdotal — not controlled-trial evidence

On r/diabetes_t2 and broader GLP-1 threads, dulaglutide users with T2D most often report A1C reductions in the 1.0–1.5% range within the first 3–6 months at 0.75–1.5mg weekly, with weight loss in the 3–8 lb range — meaningfully less than what semaglutide or tirzepatide users describe.[9] Many users note that the auto-injector device is the easiest to use of the class (a hidden needle, single-button activation, no priming required), which is frequently cited as the reason for staying on dulaglutide despite weaker weight-loss signals. The side-effect profile reported in community threads emphasizes milder nausea than semaglutide on initial titration, with more reports of indigestion and constipation than vomiting. A consistent pattern is that users seeking primarily weight loss tend to migrate to semaglutide or tirzepatide, while users prioritising T2D control with cardiovascular protection and ease of use tend to stay on dulaglutide. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding user experience but do not establish efficacy or safety claims for any specific protocol.

Sources & references (9)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]FDA approval letter, Trulicity (dulaglutide), September 2014 link
  2. [2]Glaesner W et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010;26:287–296. · PMID: 20503261 link
  3. [3]Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3). Diabetes Care 2014;37:2168–2176. · PMID: 24842985 link
  4. [4]Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–130. · PMID: 31189511 link
  5. [5]Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11). Diabetes Care 2021;44:765–773. · PMID: 33397768 link
  6. [6]ClinicalTrials.gov: SURPASS-CVOT (NCT04255433) — Cardiovascular outcomes with tirzepatide versus dulaglutide in T2D. link
  7. [7]Gerstein HC et al. Cardiovascular and renal outcomes with dulaglutide: an exploratory analysis of REWIND. Lancet 2019;394:131–138. · PMID: 31189509 link
  8. [8]Cukierman-Yaffe T et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 2020;19:582–590. · PMID: 32562683 link
  9. [9]Community report — r/diabetes_t2 dulaglutide threads (subreddit), accessed May 2026. link

Dulaglutide Calculator Input Observations

There is insufficient calculator evidence here to describe a common Dulaglutide entered amount. Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.

About Dulaglutide

Dulaglutide is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved as Trulicity for type 2 diabetes in 2014. It is structurally distinct from peptide-class GLP-1 analogs: two GLP-1 analog peptide chains are covalently linked to a human IgG4-Fc fragment, producing a much larger ~63 kDa molecule with a ~5-day half-life.

Dulaglutide is tracked under the Weight Loss category on WPA. Its reported half-life is ~5 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. FDA-approved as Trulicity (type 2 diabetes, 2014) with cardiovascular risk-reduction indication added 2020.

Frequently Asked Questions: Dulaglutide

Are current Dulaglutide offers available?

Current Dulaglutide vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

What can I check if Dulaglutide listings become available?

Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.

Does research activity establish current Dulaglutide availability?

No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.